,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rg2AB'}, 'Id': 'a0POZ00000Cd8rg2AB', 'Event_Date__c': '2020-08-04', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C24YQAS'}, 'change': None}]",Aug 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rh2AB'}, 'Id': 'a0POZ00000Cd8rh2AB', 'Event_Date__c': '2020-08-11', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C24dQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2022', 'fs': 'Jan 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8ri2AB'}, 'Id': 'a0POZ00000Cd8ri2AB', 'Event_Date__c': '2022-01-28', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 17 February 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jan 2022', 'Status_History__c': 'a132P000000DUwiQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that access to ferric carboxymaltose be widened to include patients with iron deficiency anaemia and inflammation of chronic disease with a <b>high priority</b>, subject to the following Special Authority criteria (changes in <b>bold</b> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Special Authority for Subsidy</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant </b><span style=""font-size: 11px;"">practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has been diagnosed with iron-deficiency anaemia</span><b style=""font-size: 11px;"">; and</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.1.\xa0S</b><span style=""font-size: 11px;"">erum ferritin level </span><b style=""font-size: 11px;"">is</b><span style=""font-size: 11px;""> less than or equal to 20 mcg/L</span><b style=""font-size: 11px;"">; or</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.2.\xa0Both: </b></p><p class=""ql-indent-3""><span style=""font-size: 11px;"">1.2.1.\xa0\xa0\xa0\xa0\xa0</span><b style=""font-size: 11px;"">Serum ferritin is between 20 and 50 mcg/L</b><span style=""font-size: 11px;""> and</span></p><p class=""ql-indent-3""><b style=""font-size: 11px;"">1.2.2.\xa0\xa0\xa0\xa0\xa0C-Reactive Protein (CRP) is ≥5 mg/L; and</b></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patient has been compliant with oral iron treatment and treatment has proven ineffective; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Treatment with oral iron has resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.3.\xa0\xa0Rapid correction of anaemia is required.</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant</b><span style=""font-size: 11px;""> practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><b style=""font-size: 11px;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</b><span style=""font-size: 11px;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0A re-trial with oral iron is clinically inappropriate. </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Note: Pre-treatment CRP and ferritin results are relevant where patient is receiving treatment for chronic inflammatory disease (eg prednisone).</b></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered the unmet health need of patients with iron deficiency and chronic inflammation; the challenges of diagnosing iron deficiency in this group; and the inequity of access to ferric carboxymaltose infusions in primary care.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that access to ferric carboxymaltose be widened to include patients with iron deficiency anaemia and inflammation of chronic disease with a <b>high priority</b>, subject to the following Special Authority criteria (changes in <b>bold</b> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Special Authority for Subsidy</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant </b><span style=""font-size: 11px;"">practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has been diagnosed with iron-deficiency anaemia</span><b style=""font-size: 11px;"">; and</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.1.\xa0S</b><span style=""font-size: 11px;"">erum ferritin level </span><b style=""font-size: 11px;"">is</b><span style=""font-size: 11px;""> less than or equal to 20 mcg/L</span><b style=""font-size: 11px;"">; or</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.2.\xa0Both: </b></p><p class=""ql-indent-3""><span style=""font-size: 11px;"">1.2.1.\xa0\xa0\xa0\xa0\xa0</span><b style=""font-size: 11px;"">Serum ferritin is between 20 and 50 mcg/L</b><span style=""font-size: 11px;""> and</span></p><p class=""ql-indent-3""><b style=""font-size: 11px;"">1.2.2.\xa0\xa0\xa0\xa0\xa0C-Reactive Protein (CRP) is ≥5 mg/L; and</b></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patient has been compliant with oral iron treatment and treatment has proven ineffective; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Treatment with oral iron has resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.3.\xa0\xa0Rapid correction of anaemia is required.</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant</b><span style=""font-size: 11px;""> practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><b style=""font-size: 11px;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</b><span style=""font-size: 11px;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0A re-trial with oral iron is clinically inappropriate. </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Note: Pre-treatment CRP and ferritin results are relevant where patient is receiving treatment for chronic inflammatory disease (eg prednisone).</b></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered the unmet health need of patients with iron deficiency and chronic inflammation; the challenges of diagnosing iron deficiency in this group; and the inequity of access to ferric carboxymaltose infusions in primary care.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ferric carboxymaltose (Ferinject) is an intravenous (IV) iron preparation containing 5% (50 mg per ml) elemental iron that can be administered as a single infusion for the treatment of iron deficiency anaemia. The Committee noted that ferric carboxymaltose is listed in Section H (subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/RS1417.pdf"" target=""_blank"">restriction criteria</a>) and is listed in Section B of the Pharmaceutical Schedule for the treatment of iron deficiency anaemia (prescribed by or on the recommendation of a specialist) and for patients with serum ferritin less than or equal to 20 mcg/L (prescribed by any medical practitioner) subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/SA1840.pdf"" target=""_blank"">Special Authority criteria</a>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application sought to widen access to ferric carboxymaltose in the community by allowing any practitioner in primary care to prescribe it for patients with iron deficiency anaemia and inflammation of chronic disease (defined as those with serum ferritin between 20 mcg/L and 50 mcg/L with a CRP level of 5 mg/L or greater). The Committee noted the request intended to facilitate easier access to this treatment for eligible patients who, if they were able to access a specialist opinion, could otherwise be prescribed ferric carboxymaltose on specialist recommendation – but clearly cannot in practice receive treatment because they do not have ready access to such specialist services.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients with iron deficiency anaemia who do not meet DHB criteria for funding of ferric carboxymaltose in hospital may have a need to access it in the community, however, patients encounter inequitable barriers due to the requirement for specialist approval and the administration costs of receiving this treatment. The Committee considered that in this population, iron deficiency is undertreated.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that specialist endorsement may be sought inconsistently around the country and that self-funding (where feasible for a given patient) results when unfunded treatment administration costs are passed on to the patient. The Committee considered that these access inequities are particularly challenging for patients with reduced access to specialist services and those living in rural areas.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that enabling primary care prescribers to manage ferric carboxymaltose treatment without seeking specialist endorsement would be beneficial.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that this widening of access would not address the broader access issue of self-funding treatment administration costs in the community, however, considered that prescribing ferric carboxymaltose in primary care for this subset of patients would streamline the application process and alleviate some pressure on primary care and specialists, whilst enabling access for appropriate treatment of patients with iron deficiency and potentially helping to address undertreatment.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the population with iron deficiency anaemia and inflammatory disease would primarily be those with inflammatory bowel disease (IBD) or rheumatological diseases who have a C-reactive protein (CRP) level of 5 mg/L or greater. The Committee considered that these groups of patients are iron deficient (their ferritin, an acute phase protein, is increased by the inflammatory condition) and experience an unmet health need due to their iron deficiency. Members considered that iron deficiency in these groups with chronic inflammation is often poorly recognised and not well managed with oral iron. Members further considered animal studies showing the potential for increased mucosal inflammation from oral iron therapy and considered oral iron therapy may increase the risk of IBD relapse or worsening of disease status (based on anecdotal evidence).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with chronic heart disease (CHD) or chronic kidney disease (CKD) may also have iron deficiency anaemia that would obtain clinical benefit from ferric carboxymatose. These patients would continue to need endorsement by relevant specialists as per current special authority.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the target group of patients could reasonably be defined as having a CRP of &gt;5 mg/L and ferritin of up to 50 mcg/L, as proposed by the applicant, given that a patient with chronic inflammatory disease and ferritin of less than 50 mcg/L would be expected to develop anaemia and become symptomatic. The Committee considered that, for the purposes of targeting a group for funding, no confirmed diagnosis of chronic disease would be required, nor would any other laboratory tests be required. The Committee considered that treatments for chronic inflammatory disease (eg prednisone) would impact on CRP results and therefore pre-treatment CRP and ferritin test results would be relevant. The Committee considered that in general, a timeframe of about three to six months from the test to application for funding would be expected in clinical practice, however, considered that ferric carboxymaltose would remain an appropriate option for an iron deficient patient with chronic inflammatory disease if tested more than six months earlier.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence appeared to consist of general reviews and members considered that high-quality clinical trial evidence is unlikely to be forthcoming in this area. The Committee was made aware of evidence from an analysis of a claims database that suggests intravenous iron (N=442) was associated with fewer all-cause hospitalisations and iron deficiency-related hospitalisations compared with oral iron (N=589) in patients with IBD and iron deficiency (380 patients in each group after propensity matching) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29440920/"" target=""_blank"">Stein et al. Clinicoecon Outcomes Res. 2018;10:93-103</a>). The Committee was made aware of evidence from a prospective, non-interventional, post-marketing study that treatment of 224 patients with iron deficiency and IBD resulted in quality-of-life improvements from a decrease in symptoms and an improvement in clinical scores with alleviation of anaemia symptoms, regardless of CRP level (<a href=""https://academic.oup.com/ecco-jcc/article/12/7/826/4993060"" target=""_blank"">Stein et al. J Crohns Colitis. 2018;12:826-34</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a ferritin threshold of 100 mcg/L is given in clinical guidelines and consensus statements for the treatment of iron deficiency in patients with chronic inflammatory disorders, who have CRP of 5 mg/L or greater (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599965/"" target=""_blank"">Cappellini et al. Am J Hematol. 2017;92:1068-78</a>; <a href=""https://academic.oup.com/ecco-jcc/article/9/3/211/361529"" target=""_blank"">Dignass et al. J Crohns Colitis. 2015; 9:211-22</a>). The Committee noted that the IRON CORE working group (Cappellini et al.) was convened and supported by industry, however, considered that it provided reasonable statements for patients with chronic inflammation. Overall, the Committee considered that ferritin thresholds of 50 mcg/L or 100 mcg/L may be somewhat arbitrary thresholds for treatment of iron deficiency in patients with chronic inflammation and that it was uncertain what evidence, if any, would support their use for determining eligibility to funded treatment. On balance, the Committee considered that ferritin of 50 mcg/L was reasonable for funded access to ferric carboxymaltose in the context of chronic inflammatory disease with iron deficiency.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in this way could increase eligible patient numbers by approximately 5-10%. The Committee noted that a CRP level of 5 mg/L or greater may occur in other health states with an inflammatory component (eg obesity, current influenza infection). However, the Committee considered that in practice ferric carboxymaltose would only be prescribed for those who would genuinely benefit, noting that there are barriers to overcome, and therefore it is unlikely to be overused.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ferric carboxymaltose (Ferinject) is an intravenous (IV) iron preparation containing 5% (50 mg per ml) elemental iron that can be administered as a single infusion for the treatment of iron deficiency anaemia. The Committee noted that ferric carboxymaltose is listed in Section H (subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/RS1417.pdf"" target=""_blank"">restriction criteria</a>) and is listed in Section B of the Pharmaceutical Schedule for the treatment of iron deficiency anaemia (prescribed by or on the recommendation of a specialist) and for patients with serum ferritin less than or equal to 20 mcg/L (prescribed by any medical practitioner) subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/SA1840.pdf"" target=""_blank"">Special Authority criteria</a>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application sought to widen access to ferric carboxymaltose in the community by allowing any practitioner in primary care to prescribe it for patients with iron deficiency anaemia and inflammation of chronic disease (defined as those with serum ferritin between 20 mcg/L and 50 mcg/L with a CRP level of 5 mg/L or greater). The Committee noted the request intended to facilitate easier access to this treatment for eligible patients who, if they were able to access a specialist opinion, could otherwise be prescribed ferric carboxymaltose on specialist recommendation – but clearly cannot in practice receive treatment because they do not have ready access to such specialist services.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients with iron deficiency anaemia who do not meet DHB criteria for funding of ferric carboxymaltose in hospital may have a need to access it in the community, however, patients encounter inequitable barriers due to the requirement for specialist approval and the administration costs of receiving this treatment. The Committee considered that in this population, iron deficiency is undertreated.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that specialist endorsement may be sought inconsistently around the country and that self-funding (where feasible for a given patient) results when unfunded treatment administration costs are passed on to the patient. The Committee considered that these access inequities are particularly challenging for patients with reduced access to specialist services and those living in rural areas.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that enabling primary care prescribers to manage ferric carboxymaltose treatment without seeking specialist endorsement would be beneficial.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that this widening of access would not address the broader access issue of self-funding treatment administration costs in the community, however, considered that prescribing ferric carboxymaltose in primary care for this subset of patients would streamline the application process and alleviate some pressure on primary care and specialists, whilst enabling access for appropriate treatment of patients with iron deficiency and potentially helping to address undertreatment.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the population with iron deficiency anaemia and inflammatory disease would primarily be those with inflammatory bowel disease (IBD) or rheumatological diseases who have a C-reactive protein (CRP) level of 5 mg/L or greater. The Committee considered that these groups of patients are iron deficient (their ferritin, an acute phase protein, is increased by the inflammatory condition) and experience an unmet health need due to their iron deficiency. Members considered that iron deficiency in these groups with chronic inflammation is often poorly recognised and not well managed with oral iron. Members further considered animal studies showing the potential for increased mucosal inflammation from oral iron therapy and considered oral iron therapy may increase the risk of IBD relapse or worsening of disease status (based on anecdotal evidence).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with chronic heart disease (CHD) or chronic kidney disease (CKD) may also have iron deficiency anaemia that would obtain clinical benefit from ferric carboxymatose. These patients would continue to need endorsement by relevant specialists as per current special authority.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the target group of patients could reasonably be defined as having a CRP of &gt;5 mg/L and ferritin of up to 50 mcg/L, as proposed by the applicant, given that a patient with chronic inflammatory disease and ferritin of less than 50 mcg/L would be expected to develop anaemia and become symptomatic. The Committee considered that, for the purposes of targeting a group for funding, no confirmed diagnosis of chronic disease would be required, nor would any other laboratory tests be required. The Committee considered that treatments for chronic inflammatory disease (eg prednisone) would impact on CRP results and therefore pre-treatment CRP and ferritin test results would be relevant. The Committee considered that in general, a timeframe of about three to six months from the test to application for funding would be expected in clinical practice, however, considered that ferric carboxymaltose would remain an appropriate option for an iron deficient patient with chronic inflammatory disease if tested more than six months earlier.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence appeared to consist of general reviews and members considered that high-quality clinical trial evidence is unlikely to be forthcoming in this area. The Committee was made aware of evidence from an analysis of a claims database that suggests intravenous iron (N=442) was associated with fewer all-cause hospitalisations and iron deficiency-related hospitalisations compared with oral iron (N=589) in patients with IBD and iron deficiency (380 patients in each group after propensity matching) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29440920/"" target=""_blank"">Stein et al. Clinicoecon Outcomes Res. 2018;10:93-103</a>). The Committee was made aware of evidence from a prospective, non-interventional, post-marketing study that treatment of 224 patients with iron deficiency and IBD resulted in quality-of-life improvements from a decrease in symptoms and an improvement in clinical scores with alleviation of anaemia symptoms, regardless of CRP level (<a href=""https://academic.oup.com/ecco-jcc/article/12/7/826/4993060"" target=""_blank"">Stein et al. J Crohns Colitis. 2018;12:826-34</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a ferritin threshold of 100 mcg/L is given in clinical guidelines and consensus statements for the treatment of iron deficiency in patients with chronic inflammatory disorders, who have CRP of 5 mg/L or greater (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599965/"" target=""_blank"">Cappellini et al. Am J Hematol. 2017;92:1068-78</a>; <a href=""https://academic.oup.com/ecco-jcc/article/9/3/211/361529"" target=""_blank"">Dignass et al. J Crohns Colitis. 2015; 9:211-22</a>). The Committee noted that the IRON CORE working group (Cappellini et al.) was convened and supported by industry, however, considered that it provided reasonable statements for patients with chronic inflammation. Overall, the Committee considered that ferritin thresholds of 50 mcg/L or 100 mcg/L may be somewhat arbitrary thresholds for treatment of iron deficiency in patients with chronic inflammation and that it was uncertain what evidence, if any, would support their use for determining eligibility to funded treatment. On balance, the Committee considered that ferritin of 50 mcg/L was reasonable for funded access to ferric carboxymaltose in the context of chronic inflammatory disease with iron deficiency.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in this way could increase eligible patient numbers by approximately 5-10%. The Committee noted that a CRP level of 5 mg/L or greater may occur in other health states with an inflammatory component (eg obesity, current influenza infection). However, the Committee considered that in practice ferric carboxymaltose would only be prescribed for those who would genuinely benefit, noting that there are barriers to overcome, and therefore it is unlikely to be overused.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'change': None}, 'Published_Application': {'s': '<ol><li>The Committee noted that Pharmac received a funding application in August 2020 from a clinician seeking to widen access to ferric carboxymaltose for patients with iron deficiency anaemia and inflammation of chronic disease. </li><li><span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</li></ol>', 'fs': '<ol><li>The Committee noted that Pharmac received a funding application in August 2020 from a clinician seeking to widen access to ferric carboxymaltose for patients with iron deficiency anaemia and inflammation of chronic disease. </li><li><span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</li></ol>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rj2AB'}, 'Id': 'a0POZ00000Cd8rj2AB', 'Event_Date__c': '2022-05-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 17 February 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'May 2022', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that access to ferric carboxymaltose be widened to include patients with iron deficiency anaemia and inflammation of chronic disease with a <b>high priority</b>, subject to the following Special Authority criteria (changes in <b>bold</b> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Special Authority for Subsidy</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant </b><span style=""font-size: 11px;"">practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has been diagnosed with iron-deficiency anaemia</span><b style=""font-size: 11px;"">; and</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.1.\xa0S</b><span style=""font-size: 11px;"">erum ferritin level </span><b style=""font-size: 11px;"">is</b><span style=""font-size: 11px;""> less than or equal to 20 mcg/L</span><b style=""font-size: 11px;"">; or</b></p><p class=""ql-indent-2""><b style=""font-size: 11px;"">1.2.\xa0Both: </b></p><p class=""ql-indent-3""><span style=""font-size: 11px;"">1.2.1.\xa0\xa0\xa0\xa0\xa0</span><b style=""font-size: 11px;"">Serum ferritin is between 20 and 50 mcg/L</b><span style=""font-size: 11px;""> and</span></p><p class=""ql-indent-3""><b style=""font-size: 11px;"">1.2.2.\xa0\xa0\xa0\xa0\xa0C-Reactive Protein (CRP) is ≥5 mg/L; and</b></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patient has been compliant with oral iron treatment and treatment has proven ineffective; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Treatment with oral iron has resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.3.\xa0\xa0Rapid correction of anaemia is required.</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">\xa0</b></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in chronic inflammation)</b><span style=""font-size: 11px;""> from any </span><strike style=""font-size: 11px;"">medical</strike><span style=""font-size: 11px;""> </span><b style=""font-size: 11px;"">relevant</b><span style=""font-size: 11px;""> practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><b style=""font-size: 11px;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</b><span style=""font-size: 11px;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0\xa0A re-trial with oral iron is clinically inappropriate. </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 11px;"">Note: Pre-treatment CRP and ferritin results are relevant where patient is receiving treatment for chronic inflammatory disease (eg prednisone).</b></p><p class=""ql-indent-1""><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In making this recommendation, the Committee considered the unmet health need of patients with iron deficiency and chronic inflammation; the challenges of diagnosing iron deficiency in this group; and the inequity of access to ferric carboxymaltose infusions in primary care.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'Published_Application__c': '<ol><li>The Committee noted that Pharmac received a funding application in August 2020 from a clinician seeking to widen access to ferric carboxymaltose for patients with iron deficiency anaemia and inflammation of chronic disease. </li><li><span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</li></ol>', 'Published_Discussion__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ferric carboxymaltose (Ferinject) is an intravenous (IV) iron preparation containing 5% (50 mg per ml) elemental iron that can be administered as a single infusion for the treatment of iron deficiency anaemia. The Committee noted that ferric carboxymaltose is listed in Section H (subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/RS1417.pdf"" target=""_blank"">restriction criteria</a>) and is listed in Section B of the Pharmaceutical Schedule for the treatment of iron deficiency anaemia (prescribed by or on the recommendation of a specialist) and for patients with serum ferritin less than or equal to 20 mcg/L (prescribed by any medical practitioner) subject to <a href=""https://schedule.pharmac.govt.nz/2022/03/01/SA1840.pdf"" target=""_blank"">Special Authority criteria</a>.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the application sought to widen access to ferric carboxymaltose in the community by allowing any practitioner in primary care to prescribe it for patients with iron deficiency anaemia and inflammation of chronic disease (defined as those with serum ferritin between 20 mcg/L and 50 mcg/L with a CRP level of 5 mg/L or greater). The Committee noted the request intended to facilitate easier access to this treatment for eligible patients who, if they were able to access a specialist opinion, could otherwise be prescribed ferric carboxymaltose on specialist recommendation – but clearly cannot in practice receive treatment because they do not have ready access to such specialist services.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that patients with iron deficiency anaemia who do not meet DHB criteria for funding of ferric carboxymaltose in hospital may have a need to access it in the community, however, patients encounter inequitable barriers due to the requirement for specialist approval and the administration costs of receiving this treatment. The Committee considered that in this population, iron deficiency is undertreated.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that specialist endorsement may be sought inconsistently around the country and that self-funding (where feasible for a given patient) results when unfunded treatment administration costs are passed on to the patient. The Committee considered that these access inequities are particularly challenging for patients with reduced access to specialist services and those living in rural areas.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that enabling primary care prescribers to manage ferric carboxymaltose treatment without seeking specialist endorsement would be beneficial.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that this widening of access would not address the broader access issue of self-funding treatment administration costs in the community, however, considered that prescribing ferric carboxymaltose in primary care for this subset of patients would streamline the application process and alleviate some pressure on primary care and specialists, whilst enabling access for appropriate treatment of patients with iron deficiency and potentially helping to address undertreatment.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the population with iron deficiency anaemia and inflammatory disease would primarily be those with inflammatory bowel disease (IBD) or rheumatological diseases who have a C-reactive protein (CRP) level of 5 mg/L or greater. The Committee considered that these groups of patients are iron deficient (their ferritin, an acute phase protein, is increased by the inflammatory condition) and experience an unmet health need due to their iron deficiency. Members considered that iron deficiency in these groups with chronic inflammation is often poorly recognised and not well managed with oral iron. Members further considered animal studies showing the potential for increased mucosal inflammation from oral iron therapy and considered oral iron therapy may increase the risk of IBD relapse or worsening of disease status (based on anecdotal evidence).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that patients with chronic heart disease (CHD) or chronic kidney disease (CKD) may also have iron deficiency anaemia that would obtain clinical benefit from ferric carboxymatose. These patients would continue to need endorsement by relevant specialists as per current special authority.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the target group of patients could reasonably be defined as having a CRP of &gt;5 mg/L and ferritin of up to 50 mcg/L, as proposed by the applicant, given that a patient with chronic inflammatory disease and ferritin of less than 50 mcg/L would be expected to develop anaemia and become symptomatic. The Committee considered that, for the purposes of targeting a group for funding, no confirmed diagnosis of chronic disease would be required, nor would any other laboratory tests be required. The Committee considered that treatments for chronic inflammatory disease (eg prednisone) would impact on CRP results and therefore pre-treatment CRP and ferritin test results would be relevant. The Committee considered that in general, a timeframe of about three to six months from the test to application for funding would be expected in clinical practice, however, considered that ferric carboxymaltose would remain an appropriate option for an iron deficient patient with chronic inflammatory disease if tested more than six months earlier.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence appeared to consist of general reviews and members considered that high-quality clinical trial evidence is unlikely to be forthcoming in this area. The Committee was made aware of evidence from an analysis of a claims database that suggests intravenous iron (N=442) was associated with fewer all-cause hospitalisations and iron deficiency-related hospitalisations compared with oral iron (N=589) in patients with IBD and iron deficiency (380 patients in each group after propensity matching) (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29440920/"" target=""_blank"">Stein et al. Clinicoecon Outcomes Res. 2018;10:93-103</a>). The Committee was made aware of evidence from a prospective, non-interventional, post-marketing study that treatment of 224 patients with iron deficiency and IBD resulted in quality-of-life improvements from a decrease in symptoms and an improvement in clinical scores with alleviation of anaemia symptoms, regardless of CRP level (<a href=""https://academic.oup.com/ecco-jcc/article/12/7/826/4993060"" target=""_blank"">Stein et al. J Crohns Colitis. 2018;12:826-34</a>).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee noted that a ferritin threshold of 100 mcg/L is given in clinical guidelines and consensus statements for the treatment of iron deficiency in patients with chronic inflammatory disorders, who have CRP of 5 mg/L or greater (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599965/"" target=""_blank"">Cappellini et al. Am J Hematol. 2017;92:1068-78</a>; <a href=""https://academic.oup.com/ecco-jcc/article/9/3/211/361529"" target=""_blank"">Dignass et al. J Crohns Colitis. 2015; 9:211-22</a>). The Committee noted that the IRON CORE working group (Cappellini et al.) was convened and supported by industry, however, considered that it provided reasonable statements for patients with chronic inflammation. Overall, the Committee considered that ferritin thresholds of 50 mcg/L or 100 mcg/L may be somewhat arbitrary thresholds for treatment of iron deficiency in patients with chronic inflammation and that it was uncertain what evidence, if any, would support their use for determining eligibility to funded treatment. On balance, the Committee considered that ferritin of 50 mcg/L was reasonable for funded access to ferric carboxymaltose in the context of chronic inflammatory disease with iron deficiency.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in this way could increase eligible patient numbers by approximately 5-10%. The Committee noted that a CRP level of 5 mg/L or greater may occur in other health states with an inflammatory component (eg obesity, current influenza infection). However, the Committee considered that in practice ferric carboxymaltose would only be prescribed for those who would genuinely benefit, noting that there are barriers to overcome, and therefore it is unlikely to be overused.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Committee considered that Pharmac should seek advice regarding this application from the Haematology Advisory Committee, specifically: a review of the evidence for ferric carboxymaltose in patients with iron deficiency anaemia and inflammation of chronic disease with ferritin of less than 100 mcg/L, and advice regarding Special Authority criteria for targeting treatment to the population with iron deficiency and chronic inflammation.</p>', 'Status_History__c': 'a132P000000Dkm2QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2022', 'fs': 'Jul 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rk2AB'}, 'Id': 'a0POZ00000Cd8rk2AB', 'Event_Date__c': '2022-07-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2022', 'Status_History__c': 'a13OZ000000s874YAA'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2022', 'fs': 'Oct 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Haematology Advisory Committee meeting to provide advice on Wednesday 9 November 2022', 'fs': 'Assigned to Haematology Advisory Committee meeting to provide advice on Wednesday 9 November 2022', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rl2AB'}, 'Id': 'a0POZ00000Cd8rl2AB', 'Event_Date__c': '2022-10-05', 'Event_Description__c': 'Assigned to Haematology Advisory Committee meeting to provide advice on Wednesday 9 November 2022', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2022', 'Status_History__c': 'a13OZ0000017wmiYAA'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>2.1        The Advisory Committee <strong>recommended</strong> that access to ferric carboxymaltose in the community be widened for the treatment of iron-deficiency anaemia with chronic inflammatory disease with a <strong>high</strong> priority, subject to the following Special Authority criteria (changes in <strong>bold</strong> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Special Authority for Subsidy</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been diagnosed with </span><strike style=""font-size: 9pt;"">iron-deficiency</strike><span style=""font-size: 9pt;""> anaemia; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Serum ferritin level is less than or equal to 20 mcg/L; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Serum ferritin is between 20 and 50 mcg/L and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">C-Reactive Protein (CRP) is ≥5 mg/L; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.\xa0\xa0\xa0\xa0\xa0oral iron treatment has proven ineffective; or has \xa0\xa0\xa0resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.3.\xa0\xa0\xa0\xa0\xa0Rapid Correction of anaemia is required.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><strong style=""font-size: 9pt;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</strong><span style=""font-size: 9pt;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A re-trial with oral iron is clinically inappropriate. </span></p><p><br></p><p>2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that administration in a community setting was preferable for people with iron deficiency and chronic inflammation and was desirable to address current inequity of access, as there was significant pressure on New Zealand’s infusion services and access would be enhanced for those individuals residing more rurally or in smaller centres.</p><p>2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it can be difficult to accurately diagnose iron-deficient anaemia using laboratory tests (including complete blood count (CBC) as there were no clear definitions for the condition. The Committee considered that the serum ferritin levels included in the proposed Special Authority criteria would not always indicate that someone was anaemic, however on balance the Committee considered that the serum ferritin level as specified would be clinically acceptable, as requiring additional criteria using haemoglobin thresholds would be unnecessarily restrictive in the community setting. </p><p>2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed C-reactive protein threshold in the Special Authority of 5 mg/L was at the upper end of the normal range and would be a relatively low value on which to define a significant inflammatory condition.</p><p>2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was a potential risk that by widening ferric carboxymaltose access to this expanded group of individuals in a community setting, as the potential existed for the inappropriate diagnosis and treatment of anaemic disorders.</p><p>2.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in the community for this population group would be unlikely to have a significant impact on the overall numbers of people treated. The Committee considered that most people being treated for iron deficient anaemia and chronic inflammatory disease would already be receiving access to ferric carboxymaltose in the secondary care setting.</p><p>2.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the risk of anaphylaxis associated with iron infusion with ferric carboxymaltose was very low but that community-based infusion providers have management plans in place to deal with such events.\xa0</p>', 'fs': '<p>2.1        The Advisory Committee <strong>recommended</strong> that access to ferric carboxymaltose in the community be widened for the treatment of iron-deficiency anaemia with chronic inflammatory disease with a <strong>high</strong> priority, subject to the following Special Authority criteria (changes in <strong>bold</strong> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Special Authority for Subsidy</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been diagnosed with </span><strike style=""font-size: 9pt;"">iron-deficiency</strike><span style=""font-size: 9pt;""> anaemia; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Serum ferritin level is less than or equal to 20 mcg/L; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Serum ferritin is between 20 and 50 mcg/L and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">C-Reactive Protein (CRP) is ≥5 mg/L; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.\xa0\xa0\xa0\xa0\xa0oral iron treatment has proven ineffective; or has \xa0\xa0\xa0resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.3.\xa0\xa0\xa0\xa0\xa0Rapid Correction of anaemia is required.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><strong style=""font-size: 9pt;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</strong><span style=""font-size: 9pt;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A re-trial with oral iron is clinically inappropriate. </span></p><p><br></p><p>2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that administration in a community setting was preferable for people with iron deficiency and chronic inflammation and was desirable to address current inequity of access, as there was significant pressure on New Zealand’s infusion services and access would be enhanced for those individuals residing more rurally or in smaller centres.</p><p>2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it can be difficult to accurately diagnose iron-deficient anaemia using laboratory tests (including complete blood count (CBC) as there were no clear definitions for the condition. The Committee considered that the serum ferritin levels included in the proposed Special Authority criteria would not always indicate that someone was anaemic, however on balance the Committee considered that the serum ferritin level as specified would be clinically acceptable, as requiring additional criteria using haemoglobin thresholds would be unnecessarily restrictive in the community setting. </p><p>2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed C-reactive protein threshold in the Special Authority of 5 mg/L was at the upper end of the normal range and would be a relatively low value on which to define a significant inflammatory condition.</p><p>2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was a potential risk that by widening ferric carboxymaltose access to this expanded group of individuals in a community setting, as the potential existed for the inappropriate diagnosis and treatment of anaemic disorders.</p><p>2.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in the community for this population group would be unlikely to have a significant impact on the overall numbers of people treated. The Committee considered that most people being treated for iron deficient anaemia and chronic inflammatory disease would already be receiving access to ferric carboxymaltose in the secondary care setting.</p><p>2.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the risk of anaphylaxis associated with iron infusion with ferric carboxymaltose was very low but that community-based infusion providers have management plans in place to deal with such events.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed a clinician-initiated application for widened access to ferric carboxymaltose for the treatment of anaemia and chronic inflammatory disease.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac sought advice from the Haematology Advisory Committee regarding the proposed Special Authority criteria following PTAC’s review of this application in <a href=""https://pharmac.govt.nz/assets/2022-02-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2022</a>.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed a clinician-initiated application for widened access to ferric carboxymaltose for the treatment of anaemia and chronic inflammatory disease.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac sought advice from the Haematology Advisory Committee regarding the proposed Special Authority criteria following PTAC’s review of this application in <a href=""https://pharmac.govt.nz/assets/2022-02-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2022</a>.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Haematology Advisory Committee at meeting Wednesday 9 November 2022.', 'fs': 'Clinical advice received from Haematology Advisory Committee at meeting Wednesday 9 November 2022.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rn2AB'}, 'Id': 'a0POZ00000Cd8rn2AB', 'Event_Date__c': '2023-07-10', 'Event_Description__c': 'Clinical advice received from Haematology Advisory Committee at meeting Wednesday 9 November 2022.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Jul 2023', 'Published_Recommendation__c': '<p>2.1        The Advisory Committee <strong>recommended</strong> that access to ferric carboxymaltose in the community be widened for the treatment of iron-deficiency anaemia with chronic inflammatory disease with a <strong>high</strong> priority, subject to the following Special Authority criteria (changes in <strong>bold</strong> and <strike>strikethrough</strike>):</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Special Authority for Subsidy</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Initial application – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been diagnosed with </span><strike style=""font-size: 9pt;"">iron-deficiency</strike><span style=""font-size: 9pt;""> anaemia; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Serum ferritin level is less than or equal to 20 mcg/L; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Serum ferritin is between 20 and 50 mcg/L and</span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">C-Reactive Protein (CRP) is ≥5 mg/L; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.\xa0\xa0\xa0\xa0\xa0oral iron treatment has proven ineffective; or has \xa0\xa0\xa0resulted in dose-limiting intolerance; or</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.3.\xa0\xa0\xa0\xa0\xa0Rapid Correction of anaemia is required.</span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Renewal – (serum ferritin less than or equal to 20 mcg/L, or 20 to 50 mcg/L in </span><strong style=""font-size: 9pt;"">chronic inflammatory disease</strong><span style=""font-size: 9pt;"">) from any relevant practitioner. Approval valid for 3 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/L </span><strong style=""font-size: 9pt;"">or between 20 and 50 mcg/L with CRP of ≥5 mg/L</strong><span style=""font-size: 9pt;"">; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A re-trial with oral iron is clinically inappropriate. </span></p><p><br></p><p>2.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that administration in a community setting was preferable for people with iron deficiency and chronic inflammation and was desirable to address current inequity of access, as there was significant pressure on New Zealand’s infusion services and access would be enhanced for those individuals residing more rurally or in smaller centres.</p><p>2.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that it can be difficult to accurately diagnose iron-deficient anaemia using laboratory tests (including complete blood count (CBC) as there were no clear definitions for the condition. The Committee considered that the serum ferritin levels included in the proposed Special Authority criteria would not always indicate that someone was anaemic, however on balance the Committee considered that the serum ferritin level as specified would be clinically acceptable, as requiring additional criteria using haemoglobin thresholds would be unnecessarily restrictive in the community setting. </p><p>2.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the proposed C-reactive protein threshold in the Special Authority of 5 mg/L was at the upper end of the normal range and would be a relatively low value on which to define a significant inflammatory condition.</p><p>2.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there was a potential risk that by widening ferric carboxymaltose access to this expanded group of individuals in a community setting, as the potential existed for the inappropriate diagnosis and treatment of anaemic disorders.</p><p>2.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that widening access to ferric carboxymaltose in the community for this population group would be unlikely to have a significant impact on the overall numbers of people treated. The Committee considered that most people being treated for iron deficient anaemia and chronic inflammatory disease would already be receiving access to ferric carboxymaltose in the secondary care setting.</p><p>2.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the risk of anaphylaxis associated with iron infusion with ferric carboxymaltose was very low but that community-based infusion providers have management plans in place to deal with such events.\xa0</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed a clinician-initiated application for widened access to ferric carboxymaltose for the treatment of anaemia and chronic inflammatory disease.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee noted that Pharmac sought advice from the Haematology Advisory Committee regarding the proposed Special Authority criteria following PTAC’s review of this application in <a href=""https://pharmac.govt.nz/assets/2022-02-PTAC-meeting-record-web-version.pdf"" target=""_blank"">February 2022</a>.</p>', 'Status_History__c': 'a13OZ000004DnK2YAK'}, 'change': None}]",Aug 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2022', 'fs': 'Nov 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rm2AB'}, 'Id': 'a0POZ00000Cd8rm2AB', 'Event_Date__c': '2022-11-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2022', 'Status_History__c': 'a132P000000EDavQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8ro2AB'}, 'Id': 'a0POZ00000Cd8ro2AB', 'Event_Date__c': '2023-12-05', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004E2m5YAC'}, 'change': None}]",Nov 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rp2AB'}, 'Id': 'a0POZ00000Cd8rp2AB', 'Event_Date__c': '2023-12-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004JtLSYA0'}, 'change': None}]",Dec 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a> </p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a> </p>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rq2AB'}, 'Id': 'a0POZ00000Cd8rq2AB', 'Event_Date__c': '2024-07-10', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a> </p>', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000C1XfmYAF'}, 'change': None}]",Jul 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2024', 'fs': 'Jul 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rr2AB'}, 'Id': 'a0POZ00000Cd8rr2AB', 'Event_Date__c': '2024-07-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jul 2024', 'Status_History__c': 'a13OZ00000CixaAYAR'}, 'change': None}]",Jul 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Cd8rs2AB'}, 'Id': 'a0POZ00000Cd8rs2AB', 'Event_Date__c': '2024-09-17', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EJlUiYAL'}, 'change': None}]",Sep 2024,False,True
